The frequency of very late stent thrombosis (VLST) up to 3 years after Sirolimus-Eluting Stent (SES) implantation is 0.5% to 0.6%/year, but the rate after 3 years ("very" VLST) is not known.
Background and Objective:
The frequency of very late stent thrombosis (VLST) up to 3 years after Sirolimus-Eluting Stent (SES) implantation is 0.5% to 0.6%/year, but the rate after 3 years ("very" VLST) is not known.
Methods: Diabetic and non-diabetic patients, with or without multiple diseased vessels, included in the EVASTENT matched cohort registry were followed-up 5½ years or more after stent implantation.
Results: Follow-up was obtained in 92% of the cohort (median 5.6 years). All cause deaths (including cancer and complications of diabetes), at a steady rate of 2.5%/year up to 3 years, continued at 1.2%/year beyond 3 years (difference NS). In contrast VLST (any ARC definition) was only 0.18%/year (95% Confidence interval: 0.08-0.39) after 3 years, versus 0.63%/year (CI: 0.41 to -0.98) between 1 and 3 years (p=0.03). Target lesion revascularisation (TLR) was also lower after 3 years than before 3 years (1.9% vs.7%, pd0.01), 66% of the revascularization procedures after 3 years being for non-target lesions. After 3 years,. in contrast to that before 3 years, no differences between db+ and db-were observed for TLR and ST rates. It is noteworthy that 51% of patients continued to be on clopidogrel therapy 6 years after receiving one or more SES.
Conclusion: All cause deaths continued at a steady rate over 6 years, in particular in the diabetic groups with multiple pathologies, reflecting the increased age of the population. However cardiac deaths and "very" VLST leveled out beyond 3 years. Patients in the BMS group were older, had more comorbidities, the mean stent length was lower and the average stent diameter higher, compared to DES.
Clinical and procedural characteristics were well matched between the different type of DES, except for a lower mean and total stent length in the PES group, TVF according to the type of stent are shown in the figure. TLR was higher after BMS implantation (9.9% vs. 4.3%, p=0.002) without any difference between the different type of DES. The definite ST rates were comparable whatever the stent used.
Independent predictors of TVF were BMS (OR 2.089; 95%CI 1.345-3.115, p<0.001), EES (OR 0.127; 95%CI 0.017-0.956, p=0.045) as hypertension, prior PCI and renal failure.
Conclusions:
In 'real life', BMS is independently correlated with an excess of TVF, only partly explained by the higher risk feature of the population. All kind of DES are similarly associated with a lower TLR rate without any excess of stent thrombosis at one year. EES appears independently associated with the absence of TVF.
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Five-year clinical outcome in elderly population with small vessel disease treated with drug-eluting versus bare-metal stenting Etienne Puymirat [Orateur] (1), Fabio Mangiacapra (2), Aaron Peace (2), Yiannis Ntarladimas (2), Micaela Conte (2), Jozef Bartunek (2), Marc Vanderheyden (2), William Wijns (2), Bernard De Bruyne (2), Emanuele Barbato (2) (1) AP-HP, Hôpital Européen Georges Pomipdou, Cardiologie, Paris, France -(2) Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium Background: Drug-eluting stents (DES) are more effective than baremetal stents (BMS) in the treatment of small coronary vessel lesion. There are limited data on the safety and efficacy of DES in this indication in elderly patients. We aimed to assess the long-term clinical outcome in elderly patients of DES vs. BMS in small vessel disease.
Methods:
From January 2004 to December 2008, all elderly patients (t75 years) treated with stenting of native small coronary arteries (defined as reference vessel diameter and implanted stent <3 mm) were prospectively enrolled. According to the type of stent implanted, patients were divided into BMS and DES group. Procedural and long-term clinical outcomes were compared between both groups.
Results: A total of 293 patients were enrolled (175 treated with BMS, 118 with DES). Clinical follow up was obtained in 96.2% (median follow-up 3.7 ± 1.4 years). At five years, patients treated with DES showed significantly lower major adverse cardiac events (MACE) (HR 0.42, 95%CI 0.24-0.72, logrank P=0.002) and target vessel revascularization (TVR) (HR 0.33, 95%CI 0.14-0.76, log-rank P=0.009). No significant differences were observed between the two groups as to death, myocardial infarction and stent thrombosis.
Conclusion:
In this real-world registry of small vessel disease, DES was safe and more effective than BMS in reducing MACE and TVR at 5 years in elderly patients.
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